Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Animal Study to Evaluate Potential Therapeutic Effect of DehydraTECH-CBD on Dementia
Lexaria Bioscience has launched DEM-A22-1, its first-ever study to investigate whether its patented DehydraTECH(TM)-processed CBD may have therapeutic use against dementiaThe animal study will involve a total of 32 Long Evans rats and will involve a memory assessment test that will be utilized to investigate whether CBD enables cognitive performance enhancementsPrevious independent studies have shown that CBD prevents the development of a social recognition deficit, a symptom frequently reported in Alzheimer’s disease patients, and is linked to memory impairmentThe laboratory work is expected to complete January 2023, with data and reporting to follow likely in April 2023 Lexaria Bioscience (NASDAQ:…